Prevention of Ovarian Cancer

OV.25 Women with BRCA 1/2 mutation – Acetylsalicylic acid (ASA)
Main Inclusion criteria:

  • Risk reducing surgery within 6 months to 2 years after the date of randomization

Main Exclusion criteria:

  • Prior bilateral salpingectomy
  • Prior treatment with PARP-inhibitors

Page last updated on 

We always seek feedback to make our site better.